Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Clinical Cancer Research

• Publication date

  2005-02-01

• Fields of study

  Medicine

• Identifiers
  PMID 15709194
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors

  2005cited by this paper
• Potentiation of growth suppression and modulation of the antigenic phenotype in human melanoma cells by the combination of recombinant human fibroblast and immune interferons

  2005cited by this paper
• A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer

  2004cited by this paper
• Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma.

  2004cited by this paper
• XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.

  2004cited by this paper
• ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy.

  2003cited by this paper
• Interferon-gamma reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells.

  2002cited by this paper
• Interferon- (cid:1) Reduces Melanosomal Antigen Expression and Recognition of Melanoma Cells by Cytotoxic T Cells

  2002cited by this paper
• Polymorphisms of the DNA repair gene XPD and risk of lung cancer in a Chinese population.

  2002cited by this paper
• Polymorphisms of the DNA repair gene xeroderma pigmentosum group A and risk of primary lung cancer.

  2002cited by this paper
• Presence of the human leukocyte antigen class II geneDRB1*1101 predicts interferon γ levels and disease recurrence in melanoma patients

  2002cited by this paper
• Activity of individual ERCC1 and XPF subunits in DNA nucleotide excision repair.

  2001cited by this paper
• A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer.

  2001cited by this paper
• ERCC1: A comparative genomic perspective

  2001cited by this paper
• A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer.

  2001cited by this paper
• Comparison of Serum Interleukin-10 (IL-10) Levels Between Normal Volunteers and Patients with Advanced Melanoma

  2001cited by this paper
• Significance of Plasma Cytokine Levels in Melanoma Patients With Histologically Negative Sentinel Lymph Nodes

  2001cited by this paper
• The interleukin-10 promoter genotype determines clinical immune function in hemodialysis patients.

  2001cited by this paper
• Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials.

  2000cited by this paper
• A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.

  2000cited by this paper
• A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-gamma production.

  2000cited by this paper
• Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene.

  2000cited by this paper
• A single nucleotide polymorphism in the first intron of the human IFN-γ gene:

  2000cited by this paper
• Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells.

  2000cited by this paper
• In vitro production of IFN-gamma correlates with CA repeat polymorphism in the human IFN-gamma gene.

  1999cited by this paper
• ARMS-PCR methodologies to determine IL-10, TNF-α, TNF-β and TGF-β1 gene polymorphisms

  1999cited by this paper
• Interleukin‐10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa

  1999cited by this paper
• Human DNA repair systems: An overview

  1999cited by this paper
• Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma.

  1999cited by this paper
• XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency.

  1999cited by this paper
• ARMS-PCR methodologies to determine IL-10, TNF-alpha, TNF-beta and TGF-beta 1 gene polymorphisms.

  1999cited by this paper
• XRCC1 Is Specifically Associated with Poly(ADP-Ribose) Polymerase and Negatively Regulates Its Activity following DNA Damage

  1998cited by this paper
• Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.

  1998cited by this paper
• Immunomodulatory function of interferon-gamma in patients with metastatic melanoma: results of a phase II-B trial in subjects with metastatic melanoma, ECOG study E 4987. Eastern Cooperative Oncology Group.

  1997cited by this paper
• Interleukin 10 production by human melanoma.

  1996cited by this paper
• Increased interleukin-10 serum levels in patients with solid tumours.

  1996cited by this paper
• Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study.

  1995cited by this paper
• Interleukin-10 and its receptor.

  1994cited by this paper
• Interleukin-10 and its receptor.

  1994cited by this paper
• Interferon-gamma, prototype of the proinflammatory cytokines--importance in activation, suppression, and maintenance of the immune response.

  1993cited by this paper
• Tumor escape mechanisms from immunosurveillance: induction of unresponsiveness in a specific MHC-restricted CD4+ human T cell clone by the autologous MHC class II+ melanoma.

  1993cited by this paper
• Human xeroderma pigmentosum group D gene encodes a DMA helicase

  1993cited by this paper
• Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma.

  1991cited by this paper
• IL-10 inhibits cytokine production by activated macrophages.

  1991cited by this paper
• Bootstrap investigation of the stability of a Cox regression model.

  1989cited by this paper
• Differential modulation by tumor necrosis factor and immune interferon of HLA class‐II antigens expressed by melanoma cells

  1989cited by this paper
• Differential susceptibility to recombinant interferon-gamma-induced HLA-DQ antigen modulation among clones from a human metastatic melanoma.

  1988cited by this paper
• Inflammatory cell infiltrates in human melanoma at different stages of tumor progression

  1988cited by this paper
• A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

  1987cited by this paper
• Phenotypic profile of clones from early cultures of human metastatic melanomas and its modulation by recombinant interferon γ

  1986cited by this paper
• The bootstrap and identification of prognostic factors via Cox's proportional hazards regression model.

  1985cited by this paper
• HLA-DR antigen expression in primary melanomas of the skin.

  1984cited by this paper
• The inhibition of lymphocyte stimulation by autologous human metastatic melanoma cells correlates with the expression of HLA‐DR antigens on the tumor cells

  1984cited by this paper
• Circulating immune complexes and tumor cell cytotoxins as prognostic indicators in malignant melanoma: a prospective study of 53 patients.

  1983cited by this paper
• Kinetic analysis of the in vitro binding of radioactive cis- and trans-dichlorodiammineplatinum(II) to DNA.

  1980cited by this paper
• Spontaneous regression of malignant melanoma: a review of the literature on incidence, clinical features, and possible mechanisms.

  1976cited by this paper
• Polymorphisms in the Dna Repair Genes Xrcc1 and Ercc2 and Biomarkers of Dna Damage in Human Blood Mononuclear Cells Cross-complementing Group 1) than in 399arg/arg Carriers of Breaks following Base Excision Repair (ber) Resulting From

  year unknowncited by this paper

• Single nucleotide polymorphisms: impact on susceptibility to chemotherapy in patients with colorectal cancer

  2024cites this paper
• Influence of functional variants Asp312Asn and Lys751Gln of Xeroderma Pigmentosum Group D (XPD) and Glutathione S‐transferase Mu 1 (GSTM1) and Theta 1 (GSTT1) genes on cutaneous melanoma susceptibility and prognosis

  2019cites this paper
• Genetic polymorphisms may influence the vertical growth rate of melanoma

  2018cites this paper
• Correlations of EGF G1380A, bFGF C754G and VEGF T460C polymorphisms with malignant melanoma susceptibility and prognosis: A case-control study.

  2017cites this paper
• Correlations of EGF G 1380 A , bFGF C 754 G and VEGF T 460 C polymorphisms with malignant melanoma susceptibility and prognosis : a case-control study Running title : EGF , bFGF and VEGF polymorphisms and malignant melanoma

  2017cites this paper
• Emerging Concepts in Biomarker Discovery: Cancer Immunotherapy and Degenerative Disease of the Eye as Model Systems

  2016cites this paper
• Germline determinants of clinical outcome of cutaneous melanoma

  2016influential citation
• Genetic associations of the interleukin locus at 1q32.1 with clinical outcomes of cutaneous melanoma

  2015cites this paper
• Systems biology of cisplatin resistance: past, present and future

  2014cites this paper
• CORRELATIVE ANALYSIS OF PUTATIVE MOLECULAR PREDICTIVE FACTORS IN PATIENTS WITH CURATIVELY RESECTED STAGE III COLON CANCER , TREATED WITH ADJUVANT OXALIPLATIN-BASED CHEMOTHERAPY

  2014cites this paper
• Humoral Immune Responses to EGFR-Derived Peptides Predict Progression-Free and Overall Survival of Non-Small Cell Lung Cancer Patients Receiving Gefitinib

  2014cites this paper
• Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy?

  2014cites this paper
• Low-Penetrance Variants and Susceptibility to Sporadic Malignant Melanoma

  2013cites this paper
• Applications of systems biology in cancer immunotherapy: from target discovery to biomarkers of clinical outcome

  2013cites this paper
• Are race-specific ERCC1 haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC1 N118N?

  2013cites this paper
• Approaches to Immunologic Monitoring of Clinical Trials

  2013cites this paper
• Are race-speci fi c ERCC 1 haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC 1 N 118 N ?

  2013cites this paper
• Gene expression profiles in peripheral blood as a biomarker in cancer patients receiving peptide vaccination

  2012cites this paper
• Germline melanoma susceptibility and prognostic genes: a review of the literature.

  2012cites this paper
• Melanoma & biomarkers of immunoresponsiveness

  2012cites this paper
• Polymorphisms of Nucleotide Excision Repair Genes Predict Melanoma Survival

  2012cites this paper
• A Multi-Factorial Genetic Model for Prognostic Assessment of High Risk Melanoma Patients Receiving Adjuvant Interferon

  2012cites this paper
• DNA-damage response gene polymorphisms and therapeutic outcomes in ovarian cancer

  2011cites this paper
• Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study.

  2011cites this paper
• ERCC5 p.Asp1104His and ERCC2 p.Lys751Gln polymorphisms are independent prognostic factors for the clinical course of melanoma.

  2011cites this paper
• 5 Current insights in the role of heritable genetic variation in the pharmacokinetics and pharmacodynamics of anti-cancer drugs

  2011cites this paper
• Serum TNF-α, B2M and sIL-2R levels are biological correlates of outcome in adjuvant IFN-α2b treatment of patients with melanoma

  2011cites this paper
• Genetic polymorphisms in DNA repair and oxidative stress pathways associated with malignant melanoma susceptibility.

  2011cites this paper
• Pharmacogenetics and Pharmacogenomics I: Linking Diagnostic Classification to Therapeutic Decisions

  2011cites this paper
• Association Between Polymorphisms of ERCC1 and XPD and Clinical Response to Platinum-Based Chemotherapy in Advanced Non–Small Cell Lung Cancer

  2010cites this paper
• ADAM15 expression is downregulated in melanoma metastasis compared to primary melanoma.

  2010cites this paper
• Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients.

  2010cites this paper
• DNA repair gene polymorphisms and risk of cutaneous melanoma: a systematic review and meta-analysis.

  2009cites this paper
• Single nucleotide polymorphisms in DNA repair genes XRCC1 and APEX1 in progression and survival of primary cutaneous melanoma patients.

  2009cites this paper
• Distal and proximal interleukin (IL)-10 promoter polymorphisms associated with risk of cutaneous melanoma development: a case–control study

  2009cites this paper
• Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI.

  2009cites this paper
• New take on comparative immunology: relevance to immunotherapy.

  2009influential citation
• Pharmacogenomics in dermatology: from susceptibility genes to personalized therapy

  2009cites this paper
• Immunomics of Immune Rejection

  2009cites this paper
• Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy

  2008cites this paper
• Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer.

  2008cites this paper
• Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis

  2008cites this paper
• Dendritic cells in cancer immunotherapy.

  2008cites this paper
• Cytokine-Based Therapy for Cancer

  2008cites this paper
• Prognostic and Predictive Molecular Markers in Cutaneous Malignant Melanoma: The First Step Toward Personalized Medicine

  2008cites this paper
• Melanoma immunology: past, present and future

  2007cites this paper
• Gene expression signatures of interleukin-2 in vivo and in vitro and their relation to anticancer therapy.

  2007cites this paper
• The polymorphisms of interleukin-10 gene influence the prognosis of patients with advanced melanoma.

  2007cites this paper
• Insights into the role of heritable genetic variation in the pharmacokinetics and pharmacodynamics of anticancer drugs

  2007cites this paper
• Molecular-based choice of cancer therapy: realities and expectations.

  2007cites this paper
• Update on therapy for melanoma: opportunities for patient selection and overcoming tumor resistance

  2007cites this paper
• Gene expression profiles as biomarkers for the prediction of chemotherapy drug response in human tumour cells.

  2007cites this paper
• Autologous Tumor Rejection in Humans: Trimming the Myths

  2006cites this paper
• Determinants of chemosensitivity in gastric cancer.

  2006cites this paper
• Nutrigenomics and Pharmacogenomics of Human Cancer: On the Road from Nutrigenetics and Pharmacogenetics

  2006cites this paper
• Incorporating Molecular Oncology into Prognosis

  2006cites this paper
• Polymorphisms in the DNA Repair Genes XPC, XPD, and XPG and Risk of Cutaneous Melanoma: a Case-Control Analysis

  2006cites this paper
• Association of cytokine gene polymorphisms with malignant melanoma in Caucasian population

  2006cites this paper
• Transfection of melanoma cells with antisense PAX3 oligonucleotides additively complements cisplatin-induced cytotoxicity

  2005cites this paper